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AbstrACt 
Introduction Incidence of autistic traits, mental health 
problems, stress and poor coping is high among family 
members of children with autism. These problems are 
coupled with challenging behaviour among children 
with autism. Current treatment for these families is 
disjointed and costly. The need for whole family support 
is supported by the National Institute for Health and Care 
Excellence recommendations, developments regarding 
children’s service provision, research and requests by 
families of children with autism. Despite evidence that 
family therapies can provide benefits to these families, 
efficacy has not been subject to a randomised controlled 
trial. Systemic Autism-related Family Enabling (SAFE) is 
a new family therapy intervention designed specifically 
for families of children with autism. We aim to establish 
the feasibility of running a fully powered randomised 
controlled trial to evaluate SAFE.
Methods and analysis Families of children with autism 
aged 3–16 years will be invited to participate. Consenting 
participants will be randomised 2:1 to either SAFE+support 
as usual or support as usual alone. The proposed primary 
outcome measure for the main trial will be the Systemic 
CORE 15. Participants will also complete proposed 
secondary outcome measures, indexing changes in child 
behaviour, child-parent attachment, anxiety and depression. 
Generic health economic outcome measures (EuroQol 
5 dimensions and Child Health Utility 9 Dimensions) will 
also provide data on the feasibility of cost-effectiveness 
analysis. Questionnaires will be completed at baseline 
and 32 weeks post-allocation. Data on ability to identify, 
recruit, randomise, retain and collect data from families, 
acceptability of outcome measures, adherence of therapists 
and families to the intervention, appropriateness of 
resource use questionnaires and effectiveness of training 
will be collected for feasibility analysis. Qualitative data will 
also explore acceptability of SAFE and reasons for declining 
and withdrawing from the study.
Ethics and dissemination The current trial protocol 
received ethical approval from the South West-Exeter 
Research Ethics Committee (Ref: 17/SW/0192). The 
findings of the trial will be disseminated in collaboration 
with our Family Consultation Group and other 
partners. Findings will be shared locally, nationally and 
internationally through events, conferences and published 
papers.
trial registration number ISCTRN83964946 (Pre-results) 
IRAS 213527
IntroduCtIon
More than 1% of the UK population has a 
diagnosis of autism.1 Families of children with 
autism present complex needs. Children with 
autism have impairments in social interaction, 
communication and behavioural flexibility.2 
Autism is widely accepted to have a genetic 
component and the Broad Autism Phenotype 
is disproportionally represented among family 
members.3 Mental health problems are expe-
rienced by >70% of individuals with autism 
and >50% of their parents.4 5 Individuals with 
autism suffer from high levels of anxiety and 
depression compared with those with other 
developmental conditions.6–8 Families of chil-
dren with autism have higher rates of depres-
sion, anxiety and social phobia than families 
with typically developing children, or children 
with other developmental disorders.9 Parents of 
strengths and limitations of this study
 ► The study addresses a gap in the available research 
data and will produce important feasibility informa-
tion to inform a fully powered randomised controlled 
trial.
 ► The study explores the feasibility of using measures 
of family function and a range of mental health 
measures.
 ► Quantitative feasibility data are complemented by 
qualitative focus groups and interviews.
 ► The study explores the feasibility of economic anal-
ysis measures in a population, which includes adults 
and their children with developmental disorders.
 ► The participants are recruited from two NHS Trusts 
in adjacent counties in the South West of England, 
leading to potential bias. A future randomised con-
trolled trial will extend to centres across the UK in-
cluding Scotland and Wales.
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children with autism are more likely to be hospitalised for 
mental disorders than parents of typically developing chil-
dren10; and mothers of children with autism are reported 
to have higher unmet needs, more difficulties coping and 
lower satisfaction with service interactions than mothers of 
children with other disabilities.11 Aside from these reported 
difficulties, families of children with autism can have positive 
family experiences, sense of well-being12 and positive percep-
tions of their children.13 Despite challenges, autism can be 
seen as enhancing family experience and some parents 
recognise that parenting a child with autism has added joy to 
their lives,14 made them more appreciative,15 more patient 
and compassionate.16 
As families of children with autism often exhibit psycho-
logical morbidities alongside autism, costs of services to 
treat these problems are high.17 18 Furthermore, untreated 
or unresponsive mental health problems impose societal 
costs making it hard for parents to interact effectively with 
services,19 potentially worsening outcomes for children and 
exacerbating the substantial economic burden of autism.18
Explanations for high levels of affective disorders in 
these families include: stress associated with the condition 
of autism, genetic factors and intergenerational family 
dynamics. Parenting children with autism involves stresses 
associated with challenging behaviour, lack of Theory of 
Mind and atypical attachment behaviour displayed by 
children.20 Parents of children with autism report that a 
consequent lack of psychological well-being exacerbates 
maladaptive behaviour in their children,21 which is likely to 
result in unhelpful cycles of distress and hopelessness.
Studies exploring the medical histories of family members 
indicate that the onset of affective disorders may predate the 
birth of the child9 22 23 suggesting that mental health diffi-
culties cannot be wholly accounted for by stress involved in 
parenting. It seems, therefore, that these individuals may 
have been living with psychological distress for a long period 
of time. Depression and anxiety among family members 
have been tentatively linked to genetic factors independent 
of the Broad Autism Phenotype.24 But few studies explore 
the intergenerational presence of affective disorder associ-
ated with autism.9 23
Previous research demonstrates that experience of trauma 
and abuse among women is associated with elevated risk of 
autism developing in their subsequent offspring.25 26 Hence, 
mothers of children with autism are more likely than the 
general population to be coping with previous traumatic 
events. In addition, these families often encounter difficul-
ties communicating needs to external agencies,27 which 
may trigger existing tendencies for negative affect. Fami-
lies of children with autism can experience positive family 
life, cope well with difficulties and enjoy good relationships 
with their children, but they represent a high-risk group, for 
whom treatment is disjointed, costly and inadequate.28 29
A more joined-up approach is required which focuses on 
autism-related need, coping with challenging behaviour 
and mental health difficulties by encouraging fundamental 
reflective functioning and improving family dynamics. The 
Systemic Autism-related Family Enabling (SAFE) study 
should be placed in the context of the National Institute 
for Health and Care Excellence guidelines and recommen-
dations30 31 as well as developments regarding children’s 
service provision proposed by the Munroe Report,32 33 and 
the ‘Future in Mind’ children and young people’s mental 
health report.34 The SAFE study also reflects recommenda-
tions by other researchers working in the field.35 36 Families 
of children with autism themselves highlight the importance 
of professionals working therapeutically with children and 
the wider family, in contrast to parents of children with 
conditions such as Down syndrome who tend to stress the 
support needs of their child within educational and commu-
nity settings.10
SAFE is a systemic family therapy approach designed by 
experts to address autism-related needs including mental 
health difficulties and problematic behaviour. Systemic 
family therapy is a well-recognised, evidence-based psycho-
therapeutic approach,37 which is recommended treatment 
for conditions such as conduct disorder, attention-deficit/
hyperactivity disorder and anorexia nervosa.38 Despite 
evidence that family therapy can provide benefits to children 
with autism and their parents,39 40 its efficacy for treating this 
condition has not been subject to a randomised controlled 
trial. A comprehensive search of clinical trial registries 
revealed no ongoing trials assessing systemic family therapy 
as a treatment for autism and associated mental health prob-
lems. This is surprising given guidelines and recommen-
dations for care; the successful use of family therapies for 
a range of conditions and reports documenting key areas 
of concern for the UK autism community,41 42 which over-
whelmingly show that families of children with autism want 
interventions which make real improvements to their daily 
life and sense of well-being. Consequently, the overarching 
aim of this study is to establish the feasibility of a definitive 
randomised controlled trial to evaluate SAFE therapy for 
families of children with autism.
MEthods And AnAlysIs
Participants and recruitment
Our target population are families of children with autism, 
who do not have an intellectual impairment, between the 
ages of 3 and 16 years. SAFE is designed to have a visual, 
playful approach which draws from established principles 
of family therapy, where therapists and families work as 
collaborators to solve problems and effect change. SAFE 
activities are adaptable, family led and can be used flexibly 
according to the needs of the family and the age of the child. 
Children gain most from the intervention, however, if they 
can understand and communicate their responses to SAFE 
activities. Pilot data suggest that SAFE will be most effective 
and accessible for children who do not have severe symp-
toms or an intellectual impairment. Those children who 
were non-verbal and/or had severe communication difficul-
ties found it difficult to engage with some activities. For this 
feasibility study, therefore, our target population is families 
of children with autism severity level 1 or 2 with no intellec-
tual impairment. The authors are aware that high severity 
3McKenzie R, et al. BMJ Open 2019;9:e025006. doi:10.1136/bmjopen-2018-025006
Open access
levels may not in all cases exclude children from engaging 
with SAFE and that the relationship between IQ and severity 
is complex. These issues will be explored as part of the feasi-
bility outcomes, namely our ability to recruit eligible families.
Future plans for SAFE include the development of a 
sister intervention which has extended non-verbal elements 
based on Intensive Interaction and is designed specifically 
to support families of children with autism and an intellec-
tual impairment. This feasibility study focuses on families of 
children of school-age which fits with the priorities of one 
of our secondary sources of funding. Background research 
exploring diagnostic data for our proposed centres for the 
previous 2 years revealed no children without intellectual 
impairment diagnosed before the age of 3 years. This infor-
mation strongly suggested that we would be unable to recruit 
any families with children below the age of 3 years. Conse-
quently, we focused on the 3–16 age group.
Participants will be identified and recruited from two 
study research sites: University Hospitals Plymouth NHS 
Trust (PHNT) Child Development Centre and Cornwall Part-
nership NHS Foundation Trust Autism Spectrum Disorder 
Assessment Team (ASDAT). The pathways used to identify 
and recruit families will vary according to local practice, and 
the needs of the individual families being approached. Some 
families will receive a diagnosis during the SAFE recruitment 
period, and others will have been diagnosed up to 12 months 
before the SAFE study recruitment period starts.
Families with a diagnosis during the SAFE recruitment 
period will be approached by the diagnosing paediatrician, 
who will perform an initial eligibility check, invite the fami-
lies to find out more and, if interested, refer the family to a 
member of the local SAFE study team. Families with a diag-
nosis before the SAFE study recruitment period will be iden-
tified as potentially eligible from clinic records by a suitably 
qualified member of the clinical team at each centre. Clinical 
staff in our centres and the surrounding areas are respon-
sible for diagnosis of the children within our participating 
families. If the child is recruited from a diagnostic centre 
the clinical staff also assess eligibility. The severity levels of 
the children and their intellectual ability are assessed on 
the autism pathways in Plymouth and Cornwall by a multi-
disciplinary clinical team including educational and clinical 
psychologists, speech and language therapists and paedia-
tricians. Assessment on the pathways occurs over a period 
of several months. This includes measures of IQ based on 
the Wechsler Intelligence Scale for Children (WISC-V)43 and 
measures of intellectual functioning based on the British 
Ability Scales (BAS3)44 as well as observations and detailed 
reports from the schools or nursery settings and the family.
All potential participant families will receive a participant 
information leaflet including an invitation to take part. All 
interested families will be able to speak to a member of 
the study team to discuss the study and have any questions 
answered. The participant information leaflet will contain 
information about the study in plain English. Parents will be 
asked to explain the information to younger children in a 
way that is appropriate for their child and suggestions for 
how to do this will be contained in the leaflet. A home visit 
will be arranged by a member of the study team for those 
families who express interest in participating. During the 
visit, a research assistant will provide the families with more 
detailed participant information and seek consent.
Community pathway
Participants who have received either a new diagnosis, or a 
diagnosis within the last 12 months will also be approached 
through community groups, using a recruitment poster, invi-
tation letter, reply slip, participant information leaflet and 
freepost envelope. These participants will be contacted by 
a member of the research team by telephone at which time 
they will discuss the study and answer questions. The fami-
lies will also be asked to consent to providing the original 
National Health Service (NHS) diagnosis letter, which will 
be used by the research staff to determine eligibility to partic-
ipate in the study, and legal guardianship at the first home 
visit.
Inclusion criteria
 ► Family includes child with autism spectrum  disorder 
(ASD), aged 3–16 years.
 ► Diagnosis of ASD, severity level 1 or 2.
 ► Diagnosed within 12 months of consenting to the 
study.
 ► If other diagnoses are present, ASD must be primary 
diagnosis.
 ► Family are willing to comply with study requirements.
Exclusion criteria
 ► Children with ASD severity level 3.
 ► Children with ASD and intellectual impairment*.
 ► Serious concomitant illness in child or family, or other 
circumstances such that they are unable to comply 
with study requirements.
 ► Families who may be a risk to safety of research staff 
(this will be assessed by the clinical and research staff 
on the basis of clinical records, diagnosis letter and 
contact prior to the first home visit).
 ► Insufficient English language or capacity for parent/
child to consent/assent to the study.
*Intellectual impairment will be identified by the clin-
ical staff on the basis of pathway assessments described 
above including the WISC-V and the BAS3. Impairment 
will be deemed present on the basis of any of the following 
criteria:
 ► The child has a comorbid diagnosis of intellectual 
disability.
 ► Diagnosis specifies ‘with accompanying intellectual 
impairment’.
 ► The child has been identified as requiring very 
substantial support (severity level 3) according to 
Diagnostic and Statistical Manual of Mental Disorders 
(DSM)-5 criteria for ASD.
 ► The child is being educated in a special school for 
children with intellectual disabilities.
 ► The child has an IQ of 70 or below.
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study design
This is a randomised controlled, multicentred feasibility 
study including children with autism and their families 
(See the study schema shown in figure 1.) A total of 36 
families will be recruited in four cohorts and each cohort 
will be randomised in a 2:1 ratio to receive support as 
usually employed (SUE) plus a programme of SAFE 
therapy, or SUE alone, for a period of 16 weeks. Advan-
tages of 2:1 allocation include:
 ► Increased appeal for patients deciding whether to 
consent to randomisation.
 ► Increased ability to test training of therapists, and 
ability to deliver high-fidelity treatment.
 ► Minimal reduction in statistical power for between-
groups comparisons in a full-scale evaluation.
 ► Increased ability to recruit required number of fami-
lies within an area before randomising, which will be 
closer to the figure needed if and when the interven-
tion is implemented.
Outcome assessors will be blinded to allocation. All 
participants will complete outcome measures at baseline 
and again at 32 weeks post-allocation via a face-to-face visit, 
hence each family will participate in the SAFE study for 
approximately 8 months. An embedded qualitative study 
will collect information about the feasibility and accepta-
bility of the intervention and the study itself. Qualitative 
data will be collected at a Family Feedback Day after the 
32-week post-allocation visits have been completed. The 
end date for the trial will be the date on which the last 
family completes the Family Feedback Day.
Figure 1 Study schema. ASD, autism spectrum  disorder; NHS, National Health Service; SAFE, Systemic Autism-related 
Family Enabling; SUE, support as usually employed. 
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outcome measures
Feasibility outcome measures:
 ► Ability to identify, recruit and randomise eligible 
families.
 ► Acceptability of proposed outcome measures and 
follow-up schedule to participants, and whether 
targets for loss to follow-up are achievable.
 ► Adherence of therapists and families to the 
intervention.
 ► Ability to gather quantitative data on outcomes.
 ► Appropriateness of resource use questionnaires and 
preference-based instruments for this population.
 ► Effectiveness and scalability of training arrangements.
Clinical outcome measures:
 ► Scores on the proposed primary outcome measure, 
the Systemic CORE 15 (SCORE).45 This is a 15-item 
paper-based survey, which has been shown to have 
good internal reliability (Cronbach’s α=0.89)46 and to 
be a valid index of family functioning, taking approxi-
mately 20 min to complete. The SCORE is the primary 
measure of family functioning employed in Children 
and Young People’s Improving Access to Psycholog-
ical Therapies national programme, and is the gold 
standard for assessing the impact of family therapy on 
quality of life in the UK.47 Every able family member 
will be asked to complete the SCORE, and the same 
family members should complete the SCORE at base-
line and 32 weeks. The SCORE-15 is freely available 
online.48
 ► Scores on the proposed secondary outcome measures, 
which index changes in child behaviour, child-parent 
attachment, anxiety and depression.
 – Patient Health Questionnaire (PHQ)-Somatic 
Anxiety Depressive Symptoms. This comprises the 
PHQ-9 (estimated internal reliability Cronbach’s 
α=0.86–0.89)49 measuring depression and the gen-
eralised anxiety disorder-7 (estimated internal reli-
ability α=0.92)49 measuring anxiety.50
 – Adapted mutuality subscale of the Coding of 
Attachment-Related Parenting for use with chil-
dren with Autism (CARP-A).51 The CARP-A is a 
validated observational measure of a child with 
autism’s attachment behaviour towards their carer. 
The CARP-A mutuality subscale is reported as hav-
ing inter-rater reliability of 0.74.52
 – The Child Behaviour Checklist.53 This is a 30-item 
paper-based survey, which detects emotional and 
behavioural problems. Reasonable internal reli-
ability is reported for each of three scales, given 
that some scales only have four items: (1) compe-
tence scales (Cronbach’s α=0.63–0.79), (2) prob-
lems scales (Cronbach’s α=0.78–0.97) and (3) DSM 
orientated scales (Cronbach’s α=0.72–0.91).54
 – The Reflective Functioning Questionnaire53 mea-
sures ability to understand own and others’ mental 
states (test-retest reliability coefficients are report-
ed as 0.84).55
 – Caregiving Helplessness Questionnaire (CGHQ)56. 
This is a 26-item questionnaire designed to assess 
aspects of disorganised caregiving. The CGHQ 
includes three subscales with reasonable internal 
reliability given the number of items: (1) mother 
helpless (α=0.86) includes seven items, (2) moth-
er-child frightened (α=0.66) includes six items, (3) 
child caregiving (α=0.64) includes six items.57 58
 ► Scores on generic health economic outcome meas-
ures will also provide data on the feasibility of cost-ef-
fectiveness analysis:
 – EuroQol 5 dimensions. This is a standardised ge-
neric instrument for measuring health outcome.
 – Child Health Utility 9 Dimensions. This is a paediat-
ric generic preference-based measure of health-re-
lated quality of life.
 – Resource Use Questionnaire (RUQ). A paper-based 
questionnaire completed by parent about his/her 
child’s use of healthcare and social resources. The 
RUQ is designed to identify the NHS and Social 
Care resource use for the economic evaluation. 
It includes items to establish number and type of 
health resources being used, such as number of 
general practitioner (GP) visits or number of days 
in hospital. RUQ completion will be matched with 
medical records for a subgroup of families, which 
will help to develop strategies to minimise missing 
data in the future definitive trial.
 ► Qualitative outcomes:
 – Acceptability of SAFE and the trial process for par-
ticipants and therapists.
 – Reasons for declining and withdrawing from the 
study.
The qualitative component will employ focus groups 
and interviews to investigate four key aspects of the study 
experience: families’ experiences of the study (including 
intervention and potential harm of the intervention), 
therapists’ experiences of the intervention, reasons for 
eligible families declining and reasons for families with-
drawing from the study. After the 32-week assessments 
have been completed, families will be given details of the 
qualitative focus groups and invited to attend a family 
feedback day if they wish to do so. The family feedback 
day will involve several separate focus group sessions 
organised to take place over the period of a morning or 
an afternoon at a local venue for each centre including 
focus groups aimed specifically at parents and at children. 
The families will be told at the start of the day that they 
are not obliged to respond to any question or prompt if 
they do not wish to and that the format of the day will be 
open discussion with other families in response to ques-
tions presented on a screen. They will then be invited to 
respond to a presented topic guide exploring the four key 
areas stated above through discussion with each other.
the intervention
SAFE is a manualised intensive programme of systemic 
family therapy designed to treat maladaptive autistic 
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symptoms and mental health-related difficulties encoun-
tered by families of children with autism. SAFE provides 
an array of therapeutic activities based on attachment 
theory, established systemic practice and the known visual 
processing preferences of people with autism.59–61 SAFE is 
best seen as a toolkit with a variety of activities which can 
be applied to family therapy flexibly. For example, a very 
young child will engage with activities in a different way to 
teenagers. Activities include visual tasks, drawing, model-
ling, role-play and tracking circular patterns. Sessions 
are led by family need and the therapists and family 
work collaboratively, often in a playful way, using family 
resources, therapist expertise and the tools that SAFE 
provides. SAFE draws heavily from well-documented 
active and playful approaches in family therapy practice 
and literature.62
Each therapy session will include two therapists with a 
minimum of intermediate family therapy level of quali-
fication and 4 days training in SAFE principles. Prior 
to the therapy sessions parents allocated to SAFE will 
complete an adapted version of the parent develop-
ment interview,60 which will provide therapists with back-
ground information on family experience. The reflective 
functioning questions of this interview will also be revis-
ited as an opportunity to discuss change at the 24-week 
follow-up. Between weeks 1 and 16, families allocated 
to the SAFE intervention will attend five 3-hour SAFE 
therapy sessions. Sessions 1 and 5 are multifamily sessions 
and will take place in a community setting. Sessions 2, 3 
and 4 are for individual families and will take place in a 
community venue or the family home. The therapists will 
facilitate sessions which will be video recorded, as is usual 
practice for therapy sessions. The videotapes will be used 
by the therapists in supervision sessions and preparation 
for subsequent sessions.
Following completion of the therapy programme, 
families will attend a group follow-up session at 24 
weeks post-allocation. Families will discuss any changes 
they have encountered focusing on their ability to be 
reflective about challenges faced and solutions tried. 
Trained support workers from local voluntary groups 
will attend this follow-up session and will be invited to 
give the families information about continued support 
for families of children with autism through existing 
networks.
Each session will include the following assessments for 
families to complete:
1. Client Satisfaction Questionnaire 8.
2. The Helpful Aspects of Therapy Questionnaire.
3. A Between-Session Activity (BSA) homework activity. 
Families will be encouraged to complete a pro for-
ma with key elements of the intervention as prompts 
for families to track strengths and difficulties in re-
sponse to SAFE ideas. Completion of the BSA will be 
recorded.
At the end of each session, the therapists will also 
complete a training checklist and questionnaire to 
monitor protocol adherence.
support as usually employed
Families will typically be offered a post-diagnosis 
follow-up appointment with the diagnosing paediatrician. 
Parents of children whose symptoms are not severe may 
be directed to local authority parenting classes. Classes 
such as ‘Timeout for Autism’ (Cornwall and the Isles of 
Scilly) and ‘Understanding Autism’ (Plymouth) focus 
on the features of ASD, instructional parenting tech-
niques and issues associated with education. Psychoedu-
cation may also be offered, with families being directed 
to relevant resources, for example, The National Autism 
Society, Gateway ASD and the NHS Child and Adolescent 
Mental Health Services. For families where a member 
is experiencing depression or anxiety, treatment varies 
and is not linked to autism-related care. Initial referral 
is often through the GP. Patients may receive cognitive 
behavioural therapy as part of the improved access for 
psychological therapies service. They may also receive 
medication and in extreme cases a period of inpatient 
hospital treatment.
Proposed sample size
In this feasibility trial no formal statistical testing of 
between-group differences is planned. Sample size has 
been selected heuristically with the goal of i) demon-
strating that participants can be recruited at a rate suffi-
cient to run a full-scale evaluation of SAFE at a later date; 
ii) demonstrating that it is possible to train therapists 
and deliver SAFE to patients within the study treatment 
settings and iii) demonstrate that the data collection 
procedures are effective, and that the data collection is 
acceptable to the 36 families, and not overly burdensome.
data analysis
Completed paper case report forms will be checked and 
signed by research staff before being sent to the Penin-
sula Clinical Trials Unit (CTU). Original case report form 
pages will be posted to the CTU at agreed time points for 
double-data entry on to a password-protected database, 
with copies retained at the study site. Forms will be tracked 
using a web-based trial management system. Data will be 
analysed and presented as is appropriate for a feasibility 
study, in particular concentrating on descriptive analyses 
and undertaking no formal comparisons between groups. 
Reporting will follow the principles of the CONSORT 
statement using the checklist and flow chart as recom-
mended in the CONSORT extension for randomised 
pilot and feasibility.63 The flow chart will provide details 
about the number of families approached, number 
eligible, number consenting, number randomised, 
number receiving allocated intervention and number 
assessed for outcome data at each time point. As appro-
priate, details will be given for individual members of the 
family, for example, how many family members there are 
and how many completed each questionnaire. Wherever 
possible, detailed reasons will be given for exclusions, loss 
to follow-up, non-completion of outcome measures, etc.
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Numbers will also be provided by centre and group, 
to inform the logistics of recruiting nine families prior 
to randomisation and following them up after randomi-
sation. For those randomised to the SAFE intervention, 
adherence will be reported according to the number of 
group sessions attended and participation of individual 
family members at each of the therapy sessions. Complete-
ness of data will be reported for each outcome measure at 
each relevant time point. Again this will be reported for 
individual family members as appropriate.
For each outcome measure, the relevant scores will 
be calculated and presented descriptively by trial arm. 
Where available, published guidelines will be used to 
process, score and summarise the measures including, for 
example, the use of imputation in the event of missing 
items on a questionnaire. Summary measures will be 
calculated as appropriate, for example, means and SD, 
medians and ranges, numbers and percentages in catego-
ries. These measures will be presented both for baseline 
and for the final follow-up. The only analysis contrasting 
the two groups will be an interval estimate in the form of 
a 95% CI for the primary outcome, so that the plausibility 
for the effect size used in the sample size calculation for 
the full trial can be assessed. For this purpose, the base-
line values will be used in an analysis of covariance, with 
acknowledgement that no effects are included for group 
or therapist.
Focus group interviews will be audio recorded and 
transcribed verbatim. Consequent qualitative data will 
be managed using proprietary computer-assisted qual-
itative data analysis software, for example, NVivo 10, 
and analysed thematically.64 65 Rigour of analysis will 
include ‘respondent validation’, whereby participants 
are provided with a summary of their transcript and anal-
ysis so that they can assess whether the interpretations 
being made about the data, accurately represent them. 
In addition, a second qualitative researcher will conduct 
an independent analysis of a subset of half of the focus 
group transcripts. Researchers will then meet to discuss 
and agree the findings, which will then be presented to 
the Family Consultation Group for discussion.
Patient and public involvement
Families of children with autism initiated the develop-
ment of this project by communicating their complex 
needs and dissatisfaction with current service provision 
through the Plymouth Autism Network. This Network 
was set up by the Chief Investigator in 2011 to bring 
clinicians, carers, academics and individuals with autism 
together to share ideas, research findings and experi-
ences. We further explored the challenges facing families 
of children with autism by conducting in-depth interviews 
and surveying over 90 families regarding their needs and 
the treatment they received post-diagnosis. Less than 9% 
of families agreed that current treatment helped with the 
problems they face. Our survey revealed a strong need for 
interventions, which support the whole family.
This pilot data led to the development of a research 
team within the Welcome Research Hub at Plymouth 
University, which included a Family Consultation Group. 
Our Family Consultation Group worked with us to 
develop and refine the SAFE intervention prior to the 
current project. These families have also contributed to 
the creation of a recruitment and treatment plan, which 
will be manageable for families. They have offered advice 
about how it is best to communicate with families at the 
start of the study and as it progresses. In addition, the 
Family Consultation Group representative is a co-appli-
cant on this study.
Our Family Consultation Group will continue to be 
essential members of the team and work as an advisory 
group throughout the feasibility study and beyond. 
Formal structures are in place to ensure ongoing collab-
oration with the Family Consultation Group. Specifically, 
the representative for the Consultation Group is paid as 
a research assistant on the trial and is a co-applicant. She 
attends and actively contributes to monthly trial manage-
ment group (TMG) meetings, all training sessions and 
fortnightly research team meetings. The representative 
reports key issues and requests to and from the wider 
group. Where necessary, additional meetings are held 
between the Family Consultation Group as a whole 
and other research staff. In these instances, travel and 
subsistence costs are available in line with NHS England 
guidelines on working with our patient and public voice 
partners.66
We see our Family Consultation Group as experts in 
their own lives and the lives of families with similar chal-
lenges. For this reason, we feel our role is to work with 
them in a supportive manner as collaborators. Their 
contribution is valuable in the same way as other experts 
on the team and we aim to facilitate one another.  As 
stated above, the Family Consultation Group have been 
active in contributing to the research plan. Their input 
is of particular value in developing recruitment proce-
dures, designing participant information packs and 
providing information about potential barriers to reten-
tion. We have also worked with them to prepare and 
deliver a training programme for research staff and ther-
apists. With their help we have trained recruited staff 
to work in a sensitive and informed manner with partic-
ipants. We also value their input in interpreting and 
reporting data; in particular commenting on possible 
ways to overcome challenges for the main randomised 
controlled trial.
Our families can help by identifying local networks 
and sharing their experience with new groups. Our 
Family Consultation Group are proactive campaigners 
for change and have extensive knowledge of existing 
bodies such as the National Autistic Society. They can 
also provide a family-centred perspective on research 
outcomes. They are, therefore, well-placed to collaborate 
with us in planning next steps and disseminating findings 
at local and national levels.
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EthICs And dIssEMInAtIon
risks and safety
Families of children with autism are a potentially vulner-
able group. The risks associated with participating in 
this study are however, considered minimal, with no 
adverse events anticipated in any participant. For those 
in the intervention group, there is a slight chance that 
the SAFE family therapy sessions could lead to an initial 
increase in family disagreements as family members learn 
how to change the way they solve problems and talk 
with one another. However, the purpose of the interven-
tion is ultimately to equip families with skills to handle 
these difficulties by learning how to change the way they 
solve problems and improve their communication, and 
the SAFE family therapists will be available to provide 
support and will be trained to handle any emerging prob-
lems. Should any issues arise the SAFE family therapists 
will have access to two consultant clinical psychologists to 
provide further support and advice.
During the trial, the children with autism will remain in 
the care of the Child Development Centre or the ASDAT 
and will have access to usual care should any unforeseen 
circumstances arise. Other members of the family will 
also continue to be able to seek care and advice from the 
GP or any other specialist services they are concurrently 
involved with.
Monitoring adverse events
The research team have mechanisms in place to report 
serious adverse events (SAE) related to mental health. 
SAEs related to mental health may be volunteered by 
the participant or discovered by the therapists, research 
assistants or other member of the research team during 
the SAFE family therapy sessions, or as a result of direct 
reporting (e.g. by telephone) by a family member, inde-
pendent clinician or other informant. SAEs will be 
recorded from the time of consent until the date the 
participant completes the follow-up or withdraws from 
the study.
If the CI considers that the SAE is not, or is unlikely to 
be, associated with the trial, the CTU will obtain a second 
assessment of causality from an independent assessor. Any 
SAE which in the opinion of either adjudicator is possibly 
related to the trial will be reported to the Research Ethics 
Committee (REC) within 15 days of the local research 
team having become aware of the event. All SAEs will be 
followed until either stabilised if chronic conditions, or 
resolved.
dissemination
If the feasibility study meets progression criteria an 
important part of our dissemination plan is to raise 
awareness of the need for a larger multicentre trial. We 
will, therefore, offer targeted summaries of our findings 
and presentations to policy makers. The findings will 
also be broadly disseminated, but in a manner appro-
priate to a feasibility study. We plan national conference 
presentations and published papers to inform clinicians, 
academics and therapists about the possible benefits of 
SAFE and generate interest in the future trial. We will 
make use of our existing connections including the 
Association for Family Therapy, the National Autistic 
Society and the Institute of Family Therapy to reach 
relevant audiences. Our qualitative findings will also be 
published with detailed accounts of the families’ reac-
tions to SAFE and their views on its effectiveness. We will 
also provide forums for participating families to share 
their own experiences of the intervention with wider 
audiences through existing networks, groups and events 
across the UK.
Our Family Consultation Group will be integral to 
our dissemination plan. Their involvement will include 
presenting their experiences as delegates at national 
and international conferences, being active co-authors 
on published papers, leading the organising committee 
for a local event sharing findings with families, key local 
stakeholders, clinicians and other interested partners; 
and liaising with other bodies to raise awareness of the 
study findings including Autistica, The National Autistic 
Society and the Brandon Trust.
Informing potential participants of possible benefits and 
known risks
The participant information sheets and leaflets will 
provide potential participants with information about 
the possible benefits and risks of taking part in the trial. 
For example, the participants will be informed that a 
potential risk of receiving the SAFE therapy is that the 
sessions may evoke difficult emotions and feelings; this 
could lead to family disagreement as they move towards 
change. The families will also be informed that benefits of 
the trial include the possibility of improved coping skills 
when faced with challenges and contribution to finding 
out if SAFE can progress to a national trial. Participants 
will be given the opportunity to discuss risks and benefits 
with a member of the research team prior to consenting 
to participate.
obtaining informed consent from participants
All participants will receive a leaflet and information 
sheet prior to consent. There are two versions of the 
information sheet, one for adults and one for children. In 
the leaflet, parents are encouraged to explain the trial to 
their younger children and some guidance for doing this 
is provided. The information sheet states that the partic-
ipants have the right to withdraw at any point during the 
trial and that data collected from them will be confiden-
tial. All participants will have a home-visit prior to consent 
from a member of the research team and will be able to 
ask questions or go through the information verbally. 
Participants will have the process of the study explained 
to them including the estimated time they will have to 
wait prior to randomisation and starting the intervention 
if allocated to that arm.
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data protection/confidentiality
Participants will be given a unique identification number. 
The data will be pseudo-anonymised in the sense that 
there will be an identification number on the documen-
tation but otherwise no means of identifying the indi-
vidual to which the data relates. The research team will 
ensure that participants’ pseudo-anonymity is maintained 
on all documents. Data will be collected and stored in 
accordance with the current legal and regulatory docu-
mentation. Electronic study records will be stored in a 
SQL server database, stored on a restricted access, secure 
server maintained by Plymouth University. Data will be 
entered into the database via a bespoke web-based data 
entry system encrypted using secure sockets layer (SSL). 
Access to electronic data will be permission based, and at 
the discretion of the clinical trials unit data management 
team.
Anonymised paper-based study data will be stored in 
locked filing cabinets. Copies of study data retained at the 
lead study site will be securely stored for the duration of 
the study prior to archiving. Video data will be transported 
via encrypted memory sticks and will be transferred to a 
password-protected computer. The clinical trials unit data 
team will have access to study data, including identifiable 
data. Other members of the study team and the trials unit 
will have restricted access to pseudo-anonymised study 
data. Access will be granted to the sponsor and host insti-
tution on request, to permit study-related monitoring, 
audits and inspections.
research governance and the conduct of the trial
The trial will be conducted to protect the human rights 
and dignity of the participant as reflected in the Decla-
ration of Helsinki. An important factor in protecting the 
participants is ongoing consultation with the SAFE Family 
Consultation Group. A representative of this group is a 
member of the research team and is involved in deci-
sion-making processes. The research team including the 
family consultation group are proactive in minimising 
discomfort and risk for participants, respecting their 
wishes over science and society, respecting the right to 
withdraw and the need for families to have access to all 
relevant information.
The Chief Investigator will be responsible for the overall 
conduct of the study, keeping it to schedule and within 
budget. Working closely with the CTU, she will be the 
focal contact for enquiries from both sites. The CTU will 
manage the study, liaise with sites, monitor recruitment, 
work with the sponsor and report to TMG meetings. The 
TMG will meet regularly throughout the feasibility study. 
A Trial Steering Committee (TSC) will have an overar-
ching monitoring responsibility. The TSC is expected to 
meet three times during the study, but will be additionally 
convened at the chairman or Chief Investigator’s request.
dissemination plans
If the feasibility study demonstrates successful recruit-
ment, data collection and an ability to deliver the 
intervention, an important part of the dissemination plan 
is to raise awareness of the need for a larger multicentre 
trial. Targeted summaries of the findings and presenta-
tions will be disseminated to policy makers. The find-
ings will also be broadly disseminated, but in a manner 
appropriate to a feasibility study. National conference 
presentations and published papers will be prepared to 
inform clinicians, academics and therapists about our 
feasibility results and generate interest in the future trial. 
Existing connections including the Association for Family 
Therapy, the National Autistic Society and the Institute 
of Family Therapy will be used to reach relevant audi-
ences. The qualitative findings will also be published with 
detailed accounts of the families’ reactions to SAFE and 
their views on its usefulness. A summary of study results 
in plain English will be available on the Peninsula Clinical 
Trials website.
Clinical trials authorisation and ethical approval
Clinical trials authorisation is not required. The trial will 
be conducted in accordance with the protocol, the prin-
ciples of the Declaration of Helsinki and International 
Conference of Harmonisation - Good Clinical Practice 
(ICH GCP). Any amendments of the protocol will be 
submitted to the sponsor, Health Research Authority and 
REC for approval.
trial sponsorship
The trial is sponsored by PHNT.
trial steering Committee 
The TSC will include an independent chair and two other 
independent members, along with the lead investigator 
and the other study collaborators including a parent 
representative. They will meet once a year.  
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